The potential for cost savings from the introduction of 'follow-on' versions of protein therapeutics is a major focus of the ongoing debate around the creation of a regulatory pathway for the abbreviated approval of such products. Lanthier and colleagues explore the economic issues relevant to this debate by assessing total sales, product complexity and patent expiry for current protein products.
- Michael Lanthier
- Rachel Behrman
- Clark Nardinelli
